BeiGene (ONC, .SS)_ Earnings Review_ FY24 achieved non-GAAP EBIT profitability with strong 4Q; Guidance above expectation

4Q beat with Brukinsa surpassing Calquence, FY25 guided revenue US$4.9-5.3bn: 4Q product sales of US$1.1bn (+77% y/y, +13% q/q, vs. GSe's US$1bn) were higher, mainly driven by strong Brukinsa sales in ex-China markets: 1) US sales rebounded (US$616mn, +22% q/q, vs. GSe US$552mn or VA Consensus Data US$536mn) after a slower 3Q, which was partially bolstered by US$30mn of early channel buy-in ahead of new year, 2) EU and rest-of-world (US$143mn, +20% q/q, vs. GSe US$136mn) continue to see strong ramp-up acros ...